当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Lianjie Miao
The current state of healthcare is shifting due to the fast developing field of biotechnology, which has the potential to revolutionize how illnesses are identified and treated. Healthcare biotechnology has been the topic of many great efforts, and our understanding of it has grown significantly. New biomedical paradigms are developing as a result of the most recent developments in genetics and molecular biology, igniting fresh research into brandnew solutions for human health and wellbeing. However, an exciting obstacle still exists in the practical translational development of revolutionary technological discoveries. Only a small number of biotech breakthroughs have led to brand-new, revolutionary treatments and technologies for healthcare. We shall describe the clinical translational development atmosphere for biotechnology in healthcare in this paper. Notable medical biotechnology achievements and translational promotions, including historical findings and novel perspectives are carefully covered. More groundbreaking biotech ideas are about to be translated into commercial products to bring about positive health gains, despite the fact that there are nevertheless numerous obstacles in the bench-to-bedside translational development process. This is being carried out with a tight multitude of collaboration among research institutes, healthcare providers, and industry partners.